In the United States, health insurance is meant to reduce patients’ financial risks if they require expensive medical services. It often fails to do so. The problem is particularly acute for patients who need expensive prescription medications.
Calculating the value of a good or service is a complex process. Value, after all, reflects people’s personal preferences and context that is difficult to quantify. Even under the best of circumstances, it is hard to capture factors that are inherently subjective.
Nearly half of Americans report symptoms of anxiety or depressive disorder.
RSV, or respiratory syncytial virus, is a common, highly contagious seasonal virus that affects 97% of children by the age of 2.
At some point in their lives, most patients encounter insurance delays or denials for a prescription medication. But do certain groups of patients encounter these barriers more often than others? And at what cost?
Patients with rare diseases often struggle to get a timely diagnosis and proper treatment.
On 13 July 2022, the Alliance for Patient Access’ Rare Diseases Working Group hosted a virtual discussion on primary hyperoxaluria type 1.
Tezepelumab is a novel severe asthma treatment that was approved for clinician administration in late 2021. After a few months on the market, however, several Medicare Administrative Contractors made the unprecedented decision to place tezepelumab, a biologic approved for physician administration, on the Self-Administered Drug list.
Following the success of the November 2021 focus groups for IgG4-RD patients, the Alliance for Patience Access hosted another focus group to capture additional insights.
A 2022 survey from the Alliance for Mental Health Care Access examined the effects non-medical switching has on mental health patients.